Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Aug;64(8):1402-1406.
doi: 10.1111/trf.17909. Epub 2024 Jun 7.

Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation

Moazzam Shahzad  1   2   3 , Muhammad Kashif Amin  1   3 , Polina Bellman  1 , Joe Al-Ramahi  1   3 , Jawad Noor  1 , Abhinav Vyas  1 , Zahra Mahmoudjafari  1   3 , Matthew McGuirk  1 , Shaun DeJarnette  1   3 , Nausheen Ahmed  1   3 , Al-Ola Abdallah  1   3 , Leyla Shune  1   3 , Anurag K Singh  1   3 , Joseph P McGuirk  1   3 , Sunil Abhyankar  1   3 , Muhammad Umair Mushtaq  1   3
Affiliations
Comparative Study

Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation

Moazzam Shahzad et al. Transfusion. 2024 Aug.

Abstract

Background: Nivestym, a biosimilar granulocyte colony-stimulating factor (G-CSF) to the originator filgrastim (Neupogen), is now being used for the mobilization of peripheral blood stem cells (PBSC) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aim to compare the efficacy of Nivestym and Neupogen for PBSC mobilization in healthy allogeneic donors.

Methods: We conducted a retrospective single-center study including 541 adult allo-HSCT donors receiving Nivestym (January 2013-July 2020), or Neupogen (July 2020-June 2023) for donor PBSC mobilization. Bivariate analysis was conducted using SPSS version 28. Statistical significance was determined at a p-value <.05.

Results: Our study included 541 allo-HSCT donors who received Neupogen (n = 345, 64%) or Nivestym (n = 196, 36%) for PBSC mobilization. The median age was 47 years (range 17-76). The median donor weight was 86 kg (95% confidence interval [CI]: 87-91). Donors receiving Neupogen had similar pre-G-CSF white blood cell count, CD34+ percentages, and circulating CD34+ count compared with donors receiving Nivestym. The Neupogen group had similar median PBSC product total neutrophil count, CD34+ percentage, absolute CD34+ count, and infused CD34+ dose compared with the Nivestym group. For donors aged 35 years or younger, the median CD34+ dose was higher in donors who received Neupogen compared with Nivestym (6.9 vs. 6.3 million cells/kg, p = .044).

Conclusions: Nivestym demonstrated similar efficacy for PBSC mobilization compared with Neupogen among allo-HSCT donors. In donors aged 35 years or younger, a slightly lower PBSC product CD34+ count was noted with Nivestym compared with Neupogen.

Keywords: CD34+ count; allogeneic stem cell transplant; granulocyte colony‐stimulating factor; stem cell mobilization.

PubMed Disclaimer

References

REFERENCES

    1. Janssen WE. Peripheral blood and bone marrow hematopoietic stem cells: are they the same? Semin Oncol. 1993;20(5 Suppl 6):19–27.
    1. Arslan O, Moog R. Mobilization of peripheral blood stem cells. Transfus Apher Sci. 2007;37(2):179–185. https://doi.org/10.1016/j.transci.2007.08.002
    1. Chew C, Ng HY. Efficacy and safety of Nivestim versus Neupogen for mobilization of peripheral blood stem cells for autologous stem cell transplantation. Sci Rep. 2019;9(1):19938. https://doi.org/10.1038/s41598-019-56477-w
    1. Hölig K. G‐CSF in healthy allogeneic stem cell donors. Transfus Med Hemother. 2013;40(4):225–235.
    1. Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs. 1994;48:731–760.

Publication types

LinkOut - more resources